Mobile contingency management for smoking cessation among socioeconomically disadvantaged adults: Protocol for a randomized trial.


Journal

Contemporary clinical trials
ISSN: 1559-2030
Titre abrégé: Contemp Clin Trials
Pays: United States
ID NLM: 101242342

Informations de publication

Date de publication:
03 2022
Historique:
received: 21 10 2021
revised: 26 01 2022
accepted: 26 01 2022
pubmed: 4 2 2022
medline: 1 4 2022
entrez: 3 2 2022
Statut: ppublish

Résumé

Smoking rates remain high among socioeconomically disadvantaged adults. Offering small escalating financial incentives for abstinence (i.e., contingency management [CM]), alongside clinic-based treatment dramatically increases cessation rates in this vulnerable population. However, innovative approaches are needed for those who are less able to attend office visits. The current study will evaluate an automated mobile phone-based CM approach that will allow socioeconomically disadvantaged individuals to remotely earn financial incentives for smoking cessation. The investigators have previously combined technologies, including 1) carbon monoxide monitors that connect with mobile phones to remotely verify abstinence, 2) facial recognition software to confirm identity during breath sample submissions, and 3) automated delivery of incentives triggered by biochemical abstinence confirmation. This automated CM approach will be evaluated in a randomized controlled trial of 532 low-income adults seeking cessation treatment. Participants will be randomly assigned to telephone counseling and nicotine replacement therapy (standard care [SC]) or SC plus mobile financial incentives (CM) for abstinence. Biochemically-verified 7-day point prevalence abstinence at 26 weeks post-quit is the primary outcome. The cost-effectiveness of the interventions will be evaluated. Potential treatment mechanisms, including self-efficacy, motivation, and treatment engagement, will be explored to optimize future interventions. Automated mobile CM may offer a low-cost approach to smoking cessation that can be combined with telephone counseling and pharmacological interventions. This approach represents a critical step toward the widespread dissemination of CM treatment to real-world settings, to reduce tobacco-related disease and disparities.

Sections du résumé

BACKGROUND
Smoking rates remain high among socioeconomically disadvantaged adults. Offering small escalating financial incentives for abstinence (i.e., contingency management [CM]), alongside clinic-based treatment dramatically increases cessation rates in this vulnerable population. However, innovative approaches are needed for those who are less able to attend office visits. The current study will evaluate an automated mobile phone-based CM approach that will allow socioeconomically disadvantaged individuals to remotely earn financial incentives for smoking cessation.
METHODS
The investigators have previously combined technologies, including 1) carbon monoxide monitors that connect with mobile phones to remotely verify abstinence, 2) facial recognition software to confirm identity during breath sample submissions, and 3) automated delivery of incentives triggered by biochemical abstinence confirmation. This automated CM approach will be evaluated in a randomized controlled trial of 532 low-income adults seeking cessation treatment. Participants will be randomly assigned to telephone counseling and nicotine replacement therapy (standard care [SC]) or SC plus mobile financial incentives (CM) for abstinence.
RESULTS
Biochemically-verified 7-day point prevalence abstinence at 26 weeks post-quit is the primary outcome. The cost-effectiveness of the interventions will be evaluated. Potential treatment mechanisms, including self-efficacy, motivation, and treatment engagement, will be explored to optimize future interventions.
DISCUSSION
Automated mobile CM may offer a low-cost approach to smoking cessation that can be combined with telephone counseling and pharmacological interventions. This approach represents a critical step toward the widespread dissemination of CM treatment to real-world settings, to reduce tobacco-related disease and disparities.

Identifiants

pubmed: 35114409
pii: S1551-7144(22)00027-1
doi: 10.1016/j.cct.2022.106701
pmc: PMC9514803
mid: NIHMS1780833
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT04881630']

Types de publication

Clinical Trial Protocol Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106701

Subventions

Organisme : NIMHD NIH HHS
ID : K01 MD015295
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA225520
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA251451
Pays : United States

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Références

Tob Control. 2009 Feb;18(1):43-6
pubmed: 18936053
Nicotine Tob Res. 2001 Nov;3(4):325-31
pubmed: 11694199
J Appl Behav Anal. 2013 Dec;46(4):750-64
pubmed: 24114862
Cannabis Cannabinoid Res. 2016 Dec 01;1(1):252-261
pubmed: 28861497
Nicotine Tob Res. 2009 Jun;11(6):739-49
pubmed: 19443788
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
Patient Educ Couns. 2021 May;104(5):1246-1252
pubmed: 33067081
Drug Alcohol Depend. 2014 Jul 1;140:63-8
pubmed: 24768410
Nicotine Tob Res. 2013 Nov;15(11):1934-8
pubmed: 23645606
Am J Public Health. 1987 Nov;77(11):1435-8
pubmed: 3661797
J Health Soc Behav. 2005 Sep;46(3):274-88
pubmed: 16259149
Psychol Assess. 2021 Mar;33(3):255-266
pubmed: 33779203
JAMA. 1986 Sep 12;256(10):1315-8
pubmed: 3091857
JAMA Intern Med. 2017 Dec 1;177(12):1798-1807
pubmed: 29084312
Prev Med. 1984 Jul;13(4):377-89
pubmed: 6504866
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Med Decis Making. 2005 Jul-Aug;25(4):437-48
pubmed: 16061896
Am J Public Health. 2015 Jun;105(6):1198-205
pubmed: 25393172
Arch Intern Med. 1998 Sep 14;158(16):1789-95
pubmed: 9738608
Drug Alcohol Depend. 2009 Nov 1;105(1-2):56-62
pubmed: 19615830
JMIR Mhealth Uhealth. 2020 Apr 15;8(4):e15960
pubmed: 32293568
Exp Clin Psychopharmacol. 2013 Jun;21(3):204-13
pubmed: 23750691
JAMA. 2014 Jan 8;311(2):164-71
pubmed: 24399555
Psychol Sci. 2007 Mar;18(3):233-9
pubmed: 17444920
J Environ Public Health. 2017;2017:2819372
pubmed: 28408935
N Engl J Med. 2018 Jun 14;378(24):2302-2310
pubmed: 29791259
Psychol Methods. 2010 Sep;15(3):209-33
pubmed: 20822249
Psychosomatics. 2009 Nov-Dec;50(6):613-21
pubmed: 19996233
J Gen Intern Med. 2016 Oct;31(10):1206-11
pubmed: 27170304
Psychol Bull. 1992 Jan;111(1):23-41
pubmed: 1539088
Addiction. 2008 Jun;103(6):1009-18
pubmed: 18482424
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Med Care. 2007 Nov;45(11):1026-33
pubmed: 18049342
Addiction. 2017 May;112(5):875-883
pubmed: 27923264
Child Abuse Negl. 2017 Sep;71:24-31
pubmed: 28126359
Pharmacology. 2010;85(4):234-40
pubmed: 20299823
Health Econ. 2000 Apr;9(3):227-34
pubmed: 10790701
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Du Bois Rev. 2011 Spring;8(1):95-113
pubmed: 29887911
Clin Pharmacol Ther. 2001 Mar;69(3):175-83
pubmed: 11240982
Sleep Med. 2001 Jul;2(4):297-307
pubmed: 11438246
Br J Addict. 1989 Jul;84(7):791-9
pubmed: 2758152
Annu Rev Clin Psychol. 2006;2:411-34
pubmed: 17716077
J Clin Psychiatry. 2015 Jul;76(7):959-64
pubmed: 25699616
Tob Control. 2005 Feb;14(1):37-42
pubmed: 15735298
MMWR Morb Mortal Wkly Rep. 2020 Nov 20;69(46):1736-1742
pubmed: 33211681
Med Care. 1986 Jan;24(1):67-74
pubmed: 3945130
Am J Prev Med. 1994 Mar-Apr;10(2):77-84
pubmed: 8037935
Nicotine Tob Res. 2003 Feb;5(1):13-25
pubmed: 12745503
Drug Alcohol Depend. 2021 Jul 1;224:108724
pubmed: 33940324
Exp Clin Psychopharmacol. 2015 Jun;23(3):176-83
pubmed: 25821915
Exp Clin Psychopharmacol. 2017 Oct;25(5):333-337
pubmed: 29048181
Nicotine Tob Res. 2020 Jun 12;22(7):1086-1097
pubmed: 31570931
Addict Behav. 2014 Mar;39(3):717-20
pubmed: 24321696
J Appl Behav Anal. 1996 Winter;29(4):495-504; quiz 504-5
pubmed: 8995832
Addiction. 2000 Jun;95(6):901-13
pubmed: 10946439
J Am Coll Cardiol. 2016 Aug 23;68(8):777-85
pubmed: 27539168
Nicotine Tob Res. 2009 Jan;11(1):77-83
pubmed: 19246444

Auteurs

Darla E Kendzor (DE)

Department of Family and Preventive Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America; TSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America. Electronic address: Darla-Kendzor@ouhsc.edu.

Michael S Businelle (MS)

Department of Family and Preventive Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America; TSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America.

Damon J Vidrine (DJ)

Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States of America.

Summer G Frank-Pearce (SG)

TSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America; Hudson College of Public Health, Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America.

Ya-Chen Tina Shih (YT)

Department of Health Services Research, MD Anderson Cancer Center, Houston, TX, United States of America.

Jesse Dallery (J)

Department of Psychology, University of Florida, Gainesville, FL, United States of America.

Adam C Alexander (AC)

Department of Family and Preventive Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America; TSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America.

Laili Kharazi Boozary (LK)

TSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America; Department of Psychology, Cellular and Behavioral Neurobiology, University of Oklahoma, Norman, OK, United States of America.

Joseph J C Waring (JJC)

Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States of America.

Sarah J Ehlke (SJ)

TSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH